开发针对肝脏的新型葡萄糖皮质激素前药物
Yazheng Wang1, Dandan Guo1, Rebecca Winkler1
1Department of Pharmacology, SUNY Upstate Medical University, Syracuse, NY 13210, United States.
Medicine in drug discovery
|February 23, 2024
概括
针对肝脏的新型葡萄糖皮质体 (GC) 前药,CA-DEX和CA-CB-DEX,被开发用于改善炎症性肝病和败血症的治疗. 在体内,CA-CB-DEX表现出增强的肝脏选择性和抗炎作用,需要进一步调查.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 药物运输 药物运输 药物运输
背景情况:
- 葡萄糖皮质类药物 (GCs) 对于治疗炎症性肝病和败血症至关重要.
- 系统性GC治疗受到肝外副作用的限制.
- 针对肝脏的GC前药对局部治疗具有潜在的优势.
研究的目的:
- 开发新的向肝脏的GC前药物.
- 为了改善炎症性肝病和败血症的治疗结果.
- 为了增强GC的输送,特别是到肝脏.
主要方法:
- 合成的CA-DEX和CA-CB-DEX使用胆酸 (CA) 和甲松 (DEX) 与水友链接剂.
- 在记者测定和原发性人肝细胞 (PHH) 中评估了运输体依赖活性.
- 评估了PHH,巨细胞,全血和小鼠败血症模型中的疗效.
主要成果:
- CA-CB-DEX 呈现出高水溶性和运送器依赖的活性.
- 前药物快速调节PHH中的关键GR标基因,类似于DEX.
- 与DEX相比,CA-CB-DEX在败血症小鼠肝脏中表现出优异的抗炎作用,系统性细胞因子抑制较弱.
结论:
- 在实验室中,CA-CB-DEX显示出有前途的肝细胞选择性.
- 在败血症模型中,CA-CB-DEX在体内表现出增强的抗炎疗效.
- 建议进一步评估CA-CB-DEX的炎症性肝病和败血症.
相关概念视频
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
Glucagon-like Receptor Agonists
322
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Drug Delivery: Miscellaneous Routes
339
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
339


